Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Authors

Jessica Hochberg, New York Medical CollegeFollow
Liana Klejmont, New York Medical CollegeFollow
Lauren Harrison, New York Medical CollegeFollow
Allyson M. Flower, New York Medical CollegeFollow
Qiuhu Shi, New York Medical College
Jaclyn Basso
Mitchell Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

9-2018

Journal Title

British Journal of Haematology

Department

Pediatrics

Second Department

Medicine

Third Department

Public Health

Recommended Citation

Hochberg, J., Klejmont, L., Harrison, L., Flower, A. M., Shi, Q., Basso, J., & Cairo, M. (2018). Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma. British Journal of Haematology, 182 (Suppl. 1), 59. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/412